1
|
Barron LZ, DeFrancesco TC, Chou YY, Bonagura JD, Tropf MA, Murphy SD, McManamey AK, Yuan L, Mochel JP, Ward JL. Echocardiographic caudal vena cava measurements in healthy cats and in cats with congestive heart failure and non-cardiac causes of cavitary effusions. J Vet Cardiol 2023; 48:7-18. [PMID: 37276765 DOI: 10.1016/j.jvc.2023.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 04/15/2023] [Accepted: 05/04/2023] [Indexed: 06/07/2023]
Abstract
BACKGROUND Echocardiographic indices of the inferior vena cava have been associated with elevated right atrial pressures in humans. HYPOTHESIS/OBJECTIVES Describe caudal vena caval (CVC) sonographic dimensions in healthy cats compared to cats with cardiogenic cavitary effusion (CCE), cardiogenic pulmonary edema (CPE), or non-cardiac causes of cavitary effusion (NCE). ANIMALS 30 healthy control cats and 52 client-owned cats with CCE, CPE, or NCE examined at two university hospitals. METHODS Sagittal 2-dimensional (2D) and M-mode CVC dimensions were acquired from the subxiphoid view. Caudal vena cava collapsibility index (CVC-CI) was calculated. Variables were compared between study groups using Kruskal-Wallis and Dunn's Bonferroni testing. Receiver operating characteristic curves were used to assess sensitivity and specificity for diagnostic categories. RESULTS Healthy cats had sagittal 2D and M-mode (median, interquartile range) CVC maximal dimensions of 2.4 mm (1.3-4.0) and 3.4 mm (1.5-4.9) and CVC-CI of 52% (45.2-61.8) and 55% (47.8-61.3), respectively. The CVC maximal dimensions in healthy controls were smaller than in cats with cavitary effusions or pulmonary edema (all P<0.05). CVC-CI was different between CCE and NCE (P<0.0001) with cutoffs of CVC-CI ≤38% (2D) or ≤29% (M-mode) being 90.5% and 85.7% sensitive, and 94.4% and 100% specific for diagnosis of CCE, respectively. CONCLUSIONS AND CLINICAL IMPORTANCE Caudal vena cava measurements are larger in cats with cavitary effusions and cats with CPE than healthy cats. In cats with cavitary effusion, decreased CVC-CI, ≤38% (2D) or ≤29% (M-mode), was helpful in distinguishing between cardiogenic and noncardiogenic etiology.
Collapse
Affiliation(s)
- L Z Barron
- Davies Veterinary Specialists, Manor Farm Business Park, Higham Gobion, Hitchin SG5 3HR, United Kingdom
| | - T C DeFrancesco
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Dr., Raleigh, NC, 27607, USA.
| | - Y-Y Chou
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, 1800 Christensen Dr, Ames, IA 50011, USA
| | - J D Bonagura
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Dr., Raleigh, NC, 27607, USA
| | - M A Tropf
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, 1800 Christensen Dr, Ames, IA 50011, USA
| | - S D Murphy
- Mission Veterinary Emergency & Specialty, 5914 Johnson Dr, Mission, KS 66202, USA
| | - A K McManamey
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, 625 Harrison St, West Lafayette, IN 47907, USA
| | - L Yuan
- Department of Veterinary Biomedical Sciences, College of Veterinary Medicine, Iowa State University, 1800 Christensen Dr, Ames, IA 50011, USA
| | - J P Mochel
- Department of Veterinary Biomedical Sciences, College of Veterinary Medicine, Iowa State University, 1800 Christensen Dr, Ames, IA 50011, USA
| | - J L Ward
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, 1800 Christensen Dr, Ames, IA 50011, USA
| |
Collapse
|
2
|
Smith JS, Borts DJ, Slagel CC, Rajewski SM, Bousquet-Melou A, Ferran AA, Plummer PJ, Mochel JP. Pharmacokinetics of Ertapenem in Sheep ( Ovis aries) with Experimentally Induced Urinary Tract Infection. Comp Med 2019; 69:413-418. [PMID: 31581974 DOI: 10.30802/aalas-cm-18-000144] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Sheep are commonly used as animal models for human biomedical research, but descriptions of their use for studying the pharmacokinetics of carbapenem antimicrobials, such as ertapenem, are unavailable. Ertapenem is a critical antimicrobial for human infections, and the description of the pharmacokinetics of this drug is of value for research using ovine as models for human diseases, such as urinary tract infections (UTI). There are currently no ovine models for comparative biomedical research of UTI. The objective of this study was to report the pharmacokinetics of ertapenem in sheep after single and multiple dosing. In addition, we explored the effects of an immunomodulatory drug (Zelnate) on the pharmacokinetics of ertapenem in sheep. Eight healthy ewes (weight, 64.4 ± 7.7 kg) were used in an ovine bacterial cystitis model of human cystitis with Pseudomonas aeruginosa. After disease confirmation, each ewe received 1 g of ertapenem intravenously once every 24 h for 5 administrations. Blood was collected intensively (14 samples) during 24 h after the first and last administration. After multiple-dose administration, the volume of distribution was 84.5 mL/kg, clearance was 116.3 mL/h/kg, T1/2(λz) was 1.1 h, and the extraction ratio was 0.02. No significant differences in pharmacokinetic parameters or time points were found between groups treated with the immunostimulant and controls or after the 1st or 5th administration of ertapenem. No accumulation was noted from previous administration. Our ovine pharmacokinetic findings can be used to evaluate therapeutic strategies for ertapenem use (varying drug dosing schedules and combinations with other antimicrobials or immune modulators) in the context of UTI.
Collapse
Affiliation(s)
- Joe S Smith
- Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa: Systems Modelling and Reverse Translational (SMART) Pharmacology, Iowa State University, Ames, Iowa;,
| | - David J Borts
- Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa
| | - Clare C Slagel
- Analytical Chemistry Services, Iowa State University, Ames, Iowa
| | | | | | - Aude A Ferran
- INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France
| | - Paul J Plummer
- Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa; Veterinary Microbiology and Preventative Medicine, Iowa State University, Ames, Iowa; National Institute of Antimicrobial Resistance Research and Education, Ames, Iowa
| | - Jon P Mochel
- Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa; Systems Modelling and Reverse Translational (SMART) Pharmacology, Iowa State University, Ames, Iowa
| |
Collapse
|
3
|
Bon C, Toutain PL, Concordet D, Gehring R, Martin-Jimenez T, Smith J, Pelligand L, Martinez M, Whittem T, Riviere JE, Mochel JP. Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics. J Vet Pharmacol Ther 2018; 41:171-183. [PMID: 29226975 DOI: 10.1111/jvp.12473] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Accepted: 11/16/2017] [Indexed: 01/12/2023]
Abstract
A common feature of human and veterinary pharmacokinetics is the importance of identifying and quantifying the key determinants of between-patient variability in drug disposition and effects. Some of these attributes are already well known to the field of human pharmacology such as bodyweight, age, or sex, while others are more specific to veterinary medicine, such as species, breed, and social behavior. Identification of these attributes has the potential to allow a better and more tailored use of therapeutic drugs both in companion and food-producing animals. Nonlinear mixed effects (NLME) have been purposely designed to characterize the sources of variability in drug disposition and response. The NLME approach can be used to explore the impact of population-associated variables on the relationship between drug administration, systemic exposure, and the levels of drug residues in tissues. The latter, while different from the method used by the US Food and Drug Administration for setting official withdrawal times (WT) can also be beneficial for estimating WT of approved animal drug products when used in an extralabel manner. Finally, NLME can also prove useful to optimize dosing schedules, or to analyze sparse data collected in situations where intensive blood collection is technically challenging, as in small animal species presenting limited blood volume such as poultry and fish.
Collapse
Affiliation(s)
- C Bon
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland
| | - P L Toutain
- Department of Veterinary Basic Sciences, Royal Veterinary College, Hatfield, UK
| | - D Concordet
- Toxalim, Research Centre in Food Toxicology, Toulouse, France
- Université de Toulouse, ENVT, INP, Toxalim, Toulouse, France
- Laboratoire de Physiologie et Thérapeutique, École Nationale Vétérinaire de Toulouse INRA, UMR 1331, Toulouse, France
| | - R Gehring
- Department of Anatomy and Physiology, College of Veterinary Medicine, Institute of Computational Comparative Medicine (ICCM), Kansas State University, Manhattan, KS, USA
| | - T Martin-Jimenez
- Department of Comparative Medicine, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA
| | - J Smith
- Veterinary Diagnostic and Production Animal Medicine, Iowa State University College of Veterinary Medicine, Ames, IA, USA
| | - L Pelligand
- Department of Veterinary Basic Sciences, Royal Veterinary College, Hatfield, UK
| | - M Martinez
- Center for Veterinary Medicine, US Food and Drug Administration, Rockville, MD, USA
| | - T Whittem
- Translational Research and Animal Clinical Trials (TRACTs) Group, Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Werribee, Vic., Australia
| | - J E Riviere
- Department of Anatomy and Physiology, College of Veterinary Medicine, Institute of Computational Comparative Medicine (ICCM), Kansas State University, Manhattan, KS, USA
| | - J P Mochel
- Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, USA
| |
Collapse
|
4
|
Smith JS, Coetzee JF, Fisher IWG, Borts DJ, Mochel JP. Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation. J Vet Pharmacol Ther 2018; 41:555-561. [PMID: 29603262 DOI: 10.1111/jvp.12501] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Accepted: 02/14/2018] [Indexed: 11/30/2022]
Abstract
This study describes the pharmacokinetics of intravenously administered (i.v.) fentanyl citrate, and its primary metabolite norfentanyl in Holstein calves. Eight calves (58.6 ± 2.2 kg), aged 3-4 weeks, were administered fentanyl citrate at a single dose of 5.0 μg/kg i.v. Blood samples were collected from 0 to 24 hr. Plasma (nor)fentanyl concentrations were determined using liquid chromatography with mass spectrometry and a lower limit of quantification (LLOQ) of 0.03 ng/ml. To explore the effect of analytical performance on fentanyl parameter estimation, the noncompartmental pharmacokinetic analysis was then repeated with a hypothetical LLOQ value of 0.05 ng/ml. Terminal elimination half-life was estimated at 12.7 and 3.6 hr for fentanyl and norfentanyl, respectively. For fentanyl, systemic clearance was estimated at 2.0 L hr-1 kg-1 , volume of distribution at steady-state was 24.8 L/kg and extraction ratio was 0.42. At a hypothetical LLOQ of 0.05 ng/ml fentanyl half-life, volume of distribution at steady-state and clearance were, respectively, of 3.0 hr, 8.8 L/kg and 3.4 L kg-1 hr-1 . Fentanyl citrate administered i.v. at 5.0 μg/kg can reach levels associated with analgesia in other species. Pharmacokinetic parameters should be interpreted with respect to LLOQ, as lower limits can influence estimated parameters, such as elimination half-life or systemic clearance and have significant impact on dosage regimen selection in clinical practice.
Collapse
Affiliation(s)
- J S Smith
- Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, IA, USA
| | - J F Coetzee
- Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA
| | - I W G Fisher
- Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, IA, USA
| | - D J Borts
- Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, IA, USA
| | - J P Mochel
- Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, IA, USA
| |
Collapse
|
5
|
Mochel JP, Tyden E, Hellmann K, Vendrig JC, Şenel S, Dencker L, Cristina RT, Linden H, Schmerold I. Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences. J Vet Pharmacol Ther 2017; 41:378-383. [PMID: 29266320 DOI: 10.1111/jvp.12472] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Accepted: 10/30/2017] [Indexed: 11/29/2022]
Abstract
The European Federation for Pharmaceutical Sciences (EUFEPS) was founded 25 years ago by more than 20 national pharmaceutical societies and faculty members. As a pan-European organization, it brings together pharmaceutical societies as well as academic, industrial and regulatory scientists engaged in drug research and development, drug regulation and education of professionals working in these fields. EUFEPS represents pharmaceutical sciences in Europe and is recognized as such by both the European Commission and the European Medicines Agency. EUFEPS cooperates with the European Federation of Pharmaceutical Industries and other European organizations and maintains global connections with agencies such as the US Food and Drug Administration and the American Association of Pharmaceutical Scientists. EUFEPS has established specified networks forming the basis of its activities. The creation of a Network on Veterinary Medicines is prompted by the manifold problems resulting from the use of veterinary drugs and its inherent interconnections with human medicine, environmental and public health. A long-term goal of this initiative was to expand the spectrum of available therapeutics for use in animals, including the development of innovative delivery systems.
Collapse
Affiliation(s)
- J P Mochel
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, USA
| | - E Tyden
- Division of Parasitology, Department of Biomedical Science and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | | | - J C Vendrig
- Faculty of Veterinary Medicine, Institute for Risk Assessment Sciences, Veterinary Pharmacology, Pharmacotherapy and Toxicology, Utrecht University, Utrecht, The Netherlands
| | - S Şenel
- Faculty of Pharmacy, Department of Pharmaceutical Technology, Hacettepe University, Ankara, Turkey
| | - L Dencker
- Department of Pharmaceutical Biosciences, Uppsala University Biomedical Centre, Uppsala, Sweden
| | - R T Cristina
- Faculty of Veterinary Medicine, Department of Pharmacology and Pharmacy, Banat's University of Agriculture and Veterinary Medicine "King Michael I of Romania" from Timişoara, Timişoara, Romania
| | - H Linden
- Veddesta Business Center, EUFEPS, Järfälla (Stockholm), Sweden
| | - I Schmerold
- University of Veterinary Medicine Vienna, Vienna, Austria
| |
Collapse
|
6
|
Pelligand L, Soubret A, King JN, Elliott J, Mochel JP. Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats. CPT Pharmacometrics Syst Pharmacol 2016; 5:625-635. [PMID: 27770596 PMCID: PMC5193001 DOI: 10.1002/psp4.12141] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Accepted: 09/19/2016] [Indexed: 11/11/2022] Open
Abstract
The objective of this study was to model the pharmacokinetics (PKs) of robenacoxib in cats using a nonlinear mixed-effects (NLME) approach, leveraging all available information collected from cats receiving robenacoxib s.c. and/or i.v.: 47 densely sampled laboratory cats and 36 clinical cats sparsely sampled preoperatively. Data from both routes were modeled sequentially using Monolix 4.3.2. Influence of parameter correlations and available covariates (age, gender, bodyweight, and anesthesia) on population parameter estimates were evaluated by using multiple samples from the posterior distribution of the random effects. A bicompartmental disposition model with simultaneous zero and first-order absorption best described robenacoxib PKs in blood. Clearance was 0.502 L/kg/h and the bioavailability was high (78%). The absorption constant point estimate (Ka = 0.68 h-1 ) was lower than beta (median, 1.08 h-1 ), unveiling flip-flop kinetics. No dosing adjustment based on available covariates information is advocated. This modeling work constitutes the first application of NLME in a large feline population.
Collapse
Affiliation(s)
- L Pelligand
- Royal Veterinary CollegeHatfieldUnited Kingdom
| | - A Soubret
- Department of PharmacometricsNovartis PharmaceuticalsBaselSwitzerland
| | - JN King
- Elanco Animal Health Inc.BaselSwitzerland
| | - J Elliott
- Royal Veterinary CollegeHatfieldUnited Kingdom
| | - JP Mochel
- Department of PharmacometricsNovartis PharmaceuticalsBaselSwitzerland
| |
Collapse
|
7
|
Bieth B, Bornkamp B, Toutain C, Garcia R, Mochel JP. Multiple comparison procedure and modeling: a versatile tool for evaluating dose-response relationships in veterinary pharmacology - a case study with furosemide. J Vet Pharmacol Ther 2016; 39:539-546. [PMID: 27166146 DOI: 10.1111/jvp.12313] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2015] [Accepted: 03/21/2016] [Indexed: 12/22/2022]
Abstract
Congestive heart failure (CHF) is a leading cause of mortality with an increasing prevalence in human and canine populations. While furosemide is a loop diuretic prescribed for the majority of CHF patients to reduce fluid retention, it also activates the renin-angiotensin aldosterone system (RAAS) which further contributes to the accelerated progression of heart failure. Our objective was to quantify the effect of furosemide on diuresis, renin activity (RA), and aldosterone (AL) in dogs, using a combined multiple comparisons and model-based approach (MCP-Mod). Twenty-four healthy beagle dogs were allocated to four treatment groups (saline vs. furosemide 1, 2, and 4 mg/kg i.m., q12 h for 5 days). Data from RA and AL values at furosemide trough concentrations, as well as 24-h Diuresis, were analyzed using the MCP-Mod procedure. A combination of Emax models adequately described the dose-response relationships of furosemide for the various endpoints. The dose-response curves of RA and AL were found to be well in agreement, with an apparent shallower slope compared with 24-h Diuresis. The research presented herein constitutes the first application of MCP-Mod in Veterinary Medicine. Our data show that furosemide produces a submaximal effect on diuresis at doses lower than those identified to activate the circulating RAAS.
Collapse
Affiliation(s)
- B Bieth
- Department of Pharmacometrics, Biostatistical Sciences & Pharmacometrics, Novartis Pharma AG, Basel, Switzerland.
| | - B Bornkamp
- Statistical Methodology, Biostatistical Sciences & Pharmacometrics, Novartis Pharma AG, Basel, Switzerland
| | - C Toutain
- Companion Animal Development, Novartis Animal Health, Basel, Switzerland
| | - R Garcia
- New Product Development, Novartis Animal Health US, Inc., Greensboro, NC, USA
| | - J P Mochel
- Department of Pharmacometrics, Biostatistical Sciences & Pharmacometrics, Novartis Pharma AG, Basel, Switzerland.,Department of Pharmacology, Leiden-Academic Centre for Drug Research, Leiden, The Netherlands
| |
Collapse
|
8
|
Mochel JP, Gabrielsson J, Collard W, Fink M, Gehring R, Laffont C, Liu Y, Martin-Jimenez T, Pelligand L, Steimer JL, Toutain PL, Whittem T, Riviere J. Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology. J Vet Pharmacol Ther 2013; 36:417-419. [PMID: 23713757 DOI: 10.1111/jvp.12060] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2013] [Accepted: 05/05/2013] [Indexed: 11/28/2022]
Abstract
The Animal Health Modeling & Simulation Society (AHM&S) is a newly founded association (2012) that aims to promote the development, application, and dissemination of modeling and simulation techniques in the field of Veterinary Pharmacology and Toxicology. The association is co-chaired by Pr. Johan Gabrielsson (Europe), Pr. Jim Riviere (USA), and secretary Dr. Jonathan Mochel (Switzerland). This short communication aims at presenting the membership, rationale and objectives of this group.
Collapse
Affiliation(s)
- J P Mochel
- Department of Pharmacology, Leiden-Academic Centre for Drug Research, Leiden, The Netherlands; Department of Modeling and Simulation, Novartis Pharma AG, Basel, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|